Faecal microbiota transplants aim to restore a healthy balance of bacteria in the gut of people who have recurrent C. difficile infections by introducing enteric bacteria from the faeces of healthy donors. C. difficile is a bacterium that lives harmlessly in the gut of approximately 3% of healthy people.
Status In progress
Decision Selected
Process MT
ID number 566

Provisional Schedule

Expected publication 30 August 2022

Project Team

Project lead Charlotte Pelekanou

Email enquiries


External assessment group YHEC
Others Association of British Healthcare Industries (ABHI)
  Association of Healthcare Technology Providers for Imaging, Radiotherapy and Care (AXrEM)
  Boston Scientific
  Department of Health and Social Care
  Devices for Dignity
  Greater Manchester Health & Social Care Partnership
  Healthcare Improvement Scotland
  HealthTech Alliance
  Johnson & Johnson Medical Ltd
  Medical Technology Group
  Medicines and Healthcare Products Regulatory Agency
  University of Manchester Wounds Research Group
  NHS England
  The British In Vitro Diagnostics Association (BIVDA)
  NHS Digital


Key events during the development of the guidance:

Date Update
18 July 2022 Resolution
17 June 2022 Committee meeting: 2
08 April 2022 - 11 May 2022 Draft guidance: 1
18 March 2022 Committee meeting: 1
22 September 2021 Scope published
11 August 2021 Stakeholder registration opens

For further information on our processes and methods, please see our CHTE processes and methods manual